Industry Relations Council
Participation in HOPA's Industry Relations Council is open to all organizations that support our mission and the work of hematology/oncology pharmacists. When you become an IRC participant, you are in very good company - the IRC consists of both new and established brands in pharmaceuticals, medical devices, and industry publications. We thank these companies for your recent support (view IRC participant roster.)
Download our IRC Brochure or contact Laurie Rappa, Senior Development Director, at 877.467.2791 or lrappa@hoparx.org.
The data from this trial confirm that FTD–TPI plus bevacizumab is an effective treatment option for patients with refractory metastatic colorectal cancer, irrespective of mutational status, which side the tumor is on, and whether patients have previously
